A user-friendly, frequently updated reference guide that aligns with international guidelines and protocols.
Immune Thrombocytopenia
Introduction:
It is an acquired autoimmune disorder defined by low platelet count secondary to accelerated platelet destruction or impaired thrombopoiesis by antiplatelet antibodies.
Epidemiology
5.5/1lac population/ year
Etiology:
Primary/ Idiopathic
SLE, APLA
Rheumatoid arthritis
AIDS
Immunoproliferative disorders like Hodgkin lymphoma, CLL, LGL leukemia etc.
Following viral infections such as CMV, hepatitis, EBV, rubella, mumps, HCV etc.
H. Pylori infection
Auto immune thyroiditis, Autoimmune hepatitis
Common variable immunodeficiency,Agammaglobulinemia, hypogammaglobulinemia, IgA deficiency
Following bone marrow transplantation
Post vaccination
Drug related (Drugs act as haptens or sometimes they alter the antigen on platelet surface): Quinidine, quinine, gold salts, sulphonamides, heparin, penicillins, procainamides, alpha methyl dopa etc.
Pathogenesis:
1.
Auto antibodies (usually IgG type) against platelet membrane glycoprotein IIb – IIIa, Ib-IX or Ia-IIa
↓
Formation of antigen – antibody complex
↓
Acted upon by monocyte macrophage system especially in spleen via Fc receptors of macrophages
↓
Premature removal of platelets
2.
Autoantibodies bind to megakaryocytes
↓
Decreased platelet production
3.
Platelet antigens are presented with antigen presenting cells along with CD4 cells
↓
Stimulation of B cell clones to produce anti-platelet antibodies
4.
Epitope spreading- Peptides released from phagocytosed platelets are processed and presented to T cells
↓
T cells stimulate B cells to produce additional platelet auto-antibodies
Classification:
Acute/Newly diagnosed- <3 months
Persistent- 3-12 months
Chronic- >12 months
Feature
Acute ITP
Chronic ITP
Peak age incidence
Children, 2 to 6 years
Adult 20 to 40 years
Platelet count
< 20 x 109 /L
30-80 x 109/L
Onset of bleeding
Abrupt
Insidious
Antecedent infection (viral)
Commonly 1-3 weeks before onset
Unusual
Sex predilection
None
Females 3:1
Eosinophilia and lymphocytosis
Common
More common
Hemorrhagic bullae in mouth
Present in severe cases
Rare
Spontaneous remissions
Occur in 80% of cases
Uncommon; course of disease fluctuates
Clinical Features:
Asymptomatic- Thrombocytopenia detected during routine evaluation
Hemorrhagic manifestations such as
Purpura/ Ecchymosis- Seen in areas exposed to pressure
Hemorrhagic bullae in buccal mucosa (wet purpura)- Indicates severe thrombocytopenia and it is harbinger of life-threatening bleed
Epistaxis
Bleeding gums
Malena
Hematuria
Menorrhagia
Subarachnoid hemorrhage
70-80% of childhood ITP resolve spontaneously within weeks
Investigations:
Hemogram-
Isolated thrombocytopenia
Other blood parameters are normal
Sometimes
Occasional atypical lymphocytes
Eosinophilia
Microcytic hypochromic anemia due to blood loss leading to iron deficiency
Many megathrombocytes (platelets measuring more than 2-5 µm) are seen (It indicates accelerated thrombopoiesis). But these large platelets are not more than 30% of total platelet population. In case of hereditary macrothrombocytopenia, more than 60% of platelets are large and some are giant.
Bone marrow examination
See below for indications
Megakaryocytes
Number is increased up to 5 times. But decreased number does not rule out the diagnosis of ITP.
Abundant cytoplasm with reduced cytoplasmic granularity and there is presence of vacuoles
Single, large, nonlobated/ hypolobated nucleus
Erythropoiesis and myelopoiesis are generally normal.
PT and APTT-Normal
Platelet count-Less than 1 lac/µL
Anti-platelet IgG antibody detection on platelet surface- Not recommended as their levels are elevated even in other conditions causing thrombocytopenia
Platelet survival study using 51Cr – Reduced to 2-3 days
Hess tourniquet test – positive
Sphygmomanometer cuff is inflated midway between systolic and diastolic BP.
After 5 minutes, number of petechiae below cubital fossa are counted
More than 20 petechiae indicates positive test.
Blood TPO levels- Elevated
DCT- Positive in Evan's syndrome
Measurement of Immunoglobulins-
To rule out CVID.If CVID immunosuppression must be used with caution.
IVIg is contraindicated if there is IgA deficiency.
Blood group- Rh typing is important if AntiD treatment is being considered
HIV and HCV- As thrombocytopenia due to HIV and HCV are clinically indistinguishable from ITP
H. Pylori testing- Urea breath test/ stool antigen test
Criteria for Diagnosis (International working group): Platelet count of <1,00,000/cmm, in absence of other causes or disorders that may be associated with thrombocytopenia. Presumptive diagnosis is made by exclusion i.e., after ruling out all other causes of thrombocytopenia.
No positive findings in history- No Fever/ Bone pain/ Joint pain/ family history of low platelet/ risk factors for HIV infection/ childhood history of ecchymosis
No positive findings in examination- No skeletal abnormalities/ lymphadenopathy/ splenomegaly
Complete blood count- Normal except for thrombocytopenia
Peripheral smear does not suggest other causes of thrombocytopenia, i.e. none of the following are seen
Grade 5 Life threatening/ fatal bleeding in any site
Prognosis:
Risk of fatal bleeding is 0.0162-0.0389 cases per adult patient year.
Risk of fatal bleeding increases exponentially after age of 40 years,
Bleeding and treatment related immunosuppression, both equally contribute towards mortality.
Indications for Treatment:
Adults: Platelet count <20,000/cmm with or without bleeding manifestations
Children: Only if bleeding manifestations (mild skin petechiae should not be considered as bleeding manifestation), irrespective of platelet count i.e. even if platelet count is less than 20,000/cmm, if there is no bleeding manifestation, there is no need to treat. This rule applies only if, child can be closely monitored. If child cannot be closely monitored, it is better to treat if platelet count is <20,000/cmm.
Those with thrombocytopenia, but no indications for treatment, must be
Closely followed with serial monitoring of platelet count
Advised to report if there is any bleeding manifestation
Avoid contact sports and activities which can result in trauma
Avoid NSAIDs
Goal of therapy:
To achieve platelet count that is associated with adequate hemostasis.
Usual target is 30,000/cmm
Pretreatment Work-up:
History
Examination
LN:
Spleen:
BMA and Bx (Indication: See above)
Hemoglobin
TLC, DLC
Platelet count
Peripheral smear
PT
APTT
DCT
Blood group
LFT: Bili- T/D SGPT: SGOT:Albumin: Globulin:
Creatinine
Electrolytes: Na: K:
LDH
HIV:
HBsAg:
HCV:
H. Pylori testing
Quantitative Ig: IgG: IgM: IgA:
ANA by IF
APLA workup
UPT(If h/o amenorrhea)
CMV PCR(Selected cases)
Chest X Ray
USG Abdomen
NGS for Prinmary Immunodeficiency panel: Done in young patients with chronic ITP
Treatment Plan:
Treatment must be tailored to individual patient taking into consideration following factors:
Cost
Co-morbidities
Extent of bleeding
Complications of therapy
Activity and life-style
Tolerance of side effects
Accessibility to health care
Patient expectations
In case of emergency (CNS/ GI/ Genito-urinary bleed or mucosal bleed with wet purpura)
IVIg (If this is not possible- Emergency splenectomy)
Initial treatment should include Inj. Methylprednisolone 1gm IV OD (for 2-3 days) supplemented with IVIg (1gm/Kg for 1-2 days)
Platelet transfusions- 6hrly
Vinca alkaloids
Stop drugs causing platelet dysfunction
PRBCs to maintain Hb>10gm%
Tranexamic acid- If there is no hematuria
Consider recombinant Factor VIIa
Response Criteria:
Complete response: Platelet count >1lac/cmm on 2 occasions 7 days apart
Response: Platelet count >30,000/cmm and greater than 2-fold increase in platelet count on 2 occasions 7 days apart
About Each Modality of Treatment:
Steroids:
Prednisolone- 1-2 mg/kg/d- till platelet count exceeds 50,000 / µL, then dose is gradually reduced over 4-6 weeks
Alternatively, Inj. Methylprednisolone 30mg/kg/day can be given for initial 3 days, then switch over to Oral prednisolone.
Shorter courses are preferred in children.
Response rate- Adults: 70-80%, children- 80-90%
10-30% of adults have durable responses
If there is no response after 3 weeks of steroids, then start 2nd line agent and start tapering steroids.
Mechanism of action
Inhibits interaction of immunoglobulin coated platelet with FC receptor of macrophages and inhibits phagocytosis.
Decreases autoantibody production
Improves bone marrow platelet production
Produces stabilization of blood vessels, hence bleeding will stop even if platelet count is still low
Steroid dependence: Need for ongoing or repeated administration of corticosteroids to maintain platelet counts in excess of 30,000/cmm and/or to avoid bleeding.
Pulse Dexamethasone
40mg-OD for 4 days- such 4 day courses every 14 days for 4 cycles
High risk of infection, hence should be avoided
Response rate- 86% and sustained response in 50% patients
Intravenous immunoglobulin (IVIg)
Dose - 1 g/kg – IV Administered over 4-6 hours (single dose / two doses)
Alternatively- 400mg/Kg- IV for 5 days.
In both situations, further doses can be stopped if platelet count shows significant improvement.
Given along with steroids for rapid rise in platelet count and reducing the risk of aseptic meningitis. But if steroids are contraindicated, IVIg can be used alone.
Short time for response- Platelet count increases within 24 hrs. Hence useful in emergency setting, when patient has CNS bleed or GI hemorrhage.
Improvement in platelet count is seen in 75% of patients and effect lasts for 3-4 weeks.
Mechanisms of action:
It blocks Fc receptor present on macrophages
Anti-idiotype neutralization of anti-platelet autoantibodies
Cytokine modulation
Immunomodulation by suppressing T cells and decreasing auto-antibodies
Complement neutralization
Side effects – Headache, fever – chill reaction (sometimes anaphylaxis especially in patients with IgA deficiency), aseptic meningitis, renal failure, thrombosis, transmission of infections
IV – Anti D
Premedicate with paracetamol and steroids
Given if patient is Rh positive who have not undergone splenectomy and who do not have history of AIHA.
Dose 50- 75 µg/ Kg/ day for 4-5 days
Response rate- Adults- 80%, Children- 50-80%
Anti D coats Rh +ve cells which are removed by macrophages in spleen. In this process macrophages are saturated with RBCs, whose counts are high compared to number of platelets. Hence platelets are spared.
Response is seen within 1 week of treatment
Advantages
Infused over shorter time
Produced from small donor pool
Potentially longer response
Reduces the need for splenectomy
Rituximab
Has shown good response with less toxicity.
Response rate- 60%
Response may be seen after 1 month
Durable and complete response in most of patients who respond
Dose- 375mg/m2- weekly for 4 weeks.
Alternatively 100mg-IV may be used
Contraindicated in HBV positive patients, hence check HBsAg and Hepatitis B core antigen.
Higher toxicity if given along with high dose dexamethasone
Dapsone
Dose- 100mg-OD
Avoid in patients with G6PD deficiency
Poor response in splenectomised patients
Thrombopoietin receptor agonists:
Useful because in chronic ITP despite severe thrombocytopenia TPO levels are not increased and reduced thrombopoiesis adds to low PL counts
Response rate- 80%, but fall in platelet count is observed on stopping the treatment, hence taper and stop.
May titrate the dose based on platelet counts
Eltrombopag: 25-75mg-PO-OD- 2 hrs before or after meals (Children- Start with 1.25mg/Kg-OD and then increase the dose to target platelet count between 50,000 to 1,00,000/cmm)
Romiplostim: 1-10microgm/Kg- SC- Once a week
H. Pylori eradication
This results in good improvement in platelet count
Platelet improvement is seen even if this treatment fails to eradicate H. Pylori.
Should be given to all patients who are found to have H. Pylori infection
Includes 2 weeks course of
Clarithromycin- 500mg- BD
Amoxycillin- 1000mg- BD
Pantoprazole- 20mg- BD
Azathioprine:
Dose- 150 mg/day- For about 18 months
Should be continued for at least 4 weeks before its effect is evaluated.
45% response rate
Vincristine –
Dose- 0.03 mg/kg or 1 mg every week for 6 weeks
Vinblastine-
10mg- every week for 3 weeks
Danazol-
Dose – 600 mg/day.
Avoid until puberty as it has adverse effect on growth.
Response rate- 60%
Cyclosporine
Dose- 2.5-3mg/kg/day in 2 divided doses
Maintain trough levels- 100-200ng/ml
Avoid in older patients and in those with renal insufficiency.
80% response rate
Remissions are durable
Cyclophosphamide
Dose- 1-2mg/kg- OD for at least 16 weeks
Response rate- 24-85%
Mycophenolate mofetil
Dose: Start with 250mg-OD, and then gradually increase to 1000mg/day
Response rate- 78%
Splenectomy
Removes the site of destruction and source of antibody formation
Deferred until at least 1 year from diagnosis and in children till child is > 5 years of age
If platelet count is <30,000/cmm, prior steroids and IVIg must be given to raise the platelet count, so that there is minimal risk of surgical bleeding.
Perioperative platelet transfusions may be needed if platelet counts are very low.
Prophylactic vaccination and other precautions- Refer to splenectomy section
Decision to do splenectomy depends on
Severity of thrombocytopenia and bleeding
Side effects of treatment
Fitness for surgery
Patient compliance with treatment
Patient preference
Nearly 80% of adults respond well to splenectomy initially. 2/3rd have sustained response.
Stem cell transplantation
High rates of complications including sepsis and cerebral bleeding, so not used
Management of secondary ITP:
HCV associated ITP
Start antivirals if there are no contraindications
Antiviral therapy improves platelet count
If interferon is given closely monitor platelet count, as interferon also can decrease platelet count.
If ITP needs to be treated, IVIg is initial treatment of choice.
Instead of steroids, better to give Eltrombopag as first line therapy (25-75mg-OD)
Management should be done in consultation with hepatologist
HIV associated ITP
Start HAART as soon as possible
Initial treatment should consist of IVIg with corticosteroids
If refractory, splenectomy is preferred over other second line options.
ITP secondary to primary immunodeficiency: Treatment as per the defect
ALPS or PIK3delta activation syndrome- Rapamycin inhibitors
CTLA-4- and LRBA deficient patients- CTLA-4 fusion protein therapy
GOF variants in JAK1 or JAK2- JAK inhibitors
NFATC1 variants- calcineurin inhibitors
Other Treatment Options:
Newer agents:
Oral Syk inhibitor- R788
Syk is a downstream regulator of monocyte-macrophage phagocytosis
Side effects- Diarrhea, nausea, emesis
Anti-CD40L antibody (hu5c8 and IDEC-131)
CD40 is critical for T cell dependent B cell expansion
Response rate- 15%
Special Situations:
Target platelet counts during surgery in adults
Dental prophylaxis (descaling) and simple extraction- 30,000/cmm
Complex extractions- 50,000/cmm
Minor surgery- 50,000/cmm
Major surgery- 80,000/cmm
Major neurosurgery- 1,00,000/cmm
Concomitant use of antifibrinolytics immediately prior to the procedure may be helpful.
Pregnancy and ITP
Go through "thrombocytopenia in pregnancy" in consultative hematology section. First rule out all other causes of thrombocytopenia.
In contrast to gestational thrombocytopenia, ITP is seen usually in first trimester.
Only about 30% of ITP during pregnancy need intervention
Pregnancy is a prothrombotic state, hence there is less chances of bleeding
Monitor platelet count regularly
Treat only of platelet count falls to less than 30,000/cmm or bleeding manifestations.
Maintain platelet count
>30,000/cmm- Throughout pregnancy
>50,000/cmm- For cesarian section or vaginal delivery (Mode of delivery should be based on obstetric indication)
>80,000/cmm- For spinal/epidural anesthesia
Treatment:
Prednisolone- Start with 20mg OD- Adjust to a minimal dose that produces hemostatically effective platelet count.
IVIg/ AntiD- When rapid increase in platelet count is required
Second line-
Azathioprine- Considered safe in pregnancy
Consider laparoscopic splenectomy. It is best done in 2nd trimester.
Avoid Rituximab as it inhibits fetal B cell development
Avoid IM injections to newborn till platelet counts are known
Do transcranial doppler if platelet count is <50,000/cmm
Monitor platelet count daily, as nadir is reached usually between 2nd and 5th day of life.
If platelet count is <20,000/cmm, give IVIg- 1gm/ Kg. One more may be repeated the following day if there is no improvement in platelet count.
Transfuse platelets if there is life-threatening bleeding
Fetal thrombocytopenia tends to worsen with subsequent pregnancies
Related Disorders:
Evan’s syndrome
Co-existence (either simultaneous or sequential) of ITP along with autoimmune hemolytic anemia
Generally has chronic course
Primary immunodeficiency is detected in 65% of patients, hence NGS for PID panel must be done in all cases
Differential diagnosis that must be excluded prior to diagnosis of Evan's syndrome
SLE
IgA deficiency
CVID
AIDS
ALPS
Treatment
First line: Steroids +/- IVIg
Second line: Cyclosporibe, MMF, Vincristine, Danazol, Combination of these, Rituximab
Third line: Splenectomy, Autologous stem cell transplantation
Recent advances:
New medications in treatment of ITP:
Anti CD38- Daratumumab, mezagitamab
Anti CD40- IDEC-131, hu5c8, Letolizumab
Immunoproteasome inhibitors: Bortezomib, KZR-616
FcRn inhibitors- Efgartigimod, Rozanolixizumab
Inhibitors of macrophage function: Hypersialytaed IVIg, Recombinant Fc multimers, Syk kinase inhibitors (Fostamatinib, sovleplenib), BTK inhibitors (Ibrutinib, rilzabrutinib)
Use of ATRA in ITP
All trans retinoic acid is know to exert immunomodulatory effect and promote thrombopoiesis. A study from China, looked at use of ATRA as upfront therapy in newly diagnosed patients with ITP. Compared to standard arm, patients in experimental arm, received ATRA (10mg BD for 12 weeks) in addition to high dose dexamethasone (40mg OD for 4 days). At 6 months, a significantly higher proportion of participants in the all-trans retinoic acid plus high-dose dexamethasone group (68%) than in the high-dose dexamethasonemonotherapy group (41%) had a sustained response.
Most of the vaccines used in prevention of SARS-CoV-2 infection increase the risk of development of de-novo and relapse of ITP. The French National Agency for the Safety of Medicine and Health Products set up an active monitoring for COVID-19 vaccine adverse drug reactions. The median time from vaccination to ITP onset was 11 days. 12% patients were only observed, 64% patients recovered with steroids and rest were treated with TPO agonists/ rituximab. Out of 7 patients who were rechallenged with vaccine 3 had relapse of ITP.
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia
Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton’s tyrosine kinase was tested in patients with immune thrombocytopenia. It acts mainly through 2 mechanisms: decreasing macrophage mediated platelet destruction and reducing production of pathogenic autoantibodies. Trial involved 60 patients of chronic ITP with median duration of disease 6.3 years. At a median of 167 days of treatment, 24 of 60 patients (40%) showed significant increment in platelet counts.
Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study
Eltrombopag is a TPO-RA approved in Europe for treatment of patients aged ≥1 year, with ITP lasting ≥6 months from diagnosis refractory to other treatments (e.g. corticosteroids). This subanalysis of EXTEND study assessed whether eltrombopag efficacy and/or safety were different among patients with and without prior rituximab treatment.Eltrombopag was effective and generally well tolerated, regardless of previous rituximab, splenectomy, or both.
Avatrombopag is a new oral TPO-RA. In the present retrospective observational study, adults with ITP who switched from eltrombopag or romiplostim to avatrombopag were evaluated. On avatrombopag, 41/44 patients (93%) achieved a platelet response (≥50 × 109/l) and 38/44 patients (86%) achieved a complete response (≥100 × 109/l).
https://doi.org/10.1111/bjh.18081
Should dexamethasone alone or in combination be the initial steroid for adult ITP: Still a relevant question
Four-day cycles of dexamethasone work faster in increasing platelet counts and appear to reduce the occurrence of severe adverse events. Therefore, it is probably a better option for patients with low platelet counts and bleeding diathesis; however, curative superiority, the initial reason to administer it, compared to PDN is not well demonstrated. Dexamethasone in combination with rituximab in first-line treatment produced higher response rates with better long-term results compared to high-dose dexamethasone alone and is a particularly good option in younger women.
Antinuclear antibody titre in children with primary immune thrombocytopenia
This study examined the impact of antinuclear antibody (ANA) titre in children with primary immune thrombocytopenia (ITP) through a retrospective cohort study of 324 children at Peking Union Medical College Hospital. 39.2% had ANA titres of 1:160 or higher. Patients with higher ANA titres exhibited lower platelet counts at onset but had a higher rate of subsequent platelet count recovery. Moreover, patients with ANA titres of 1:160 or higher were more likely to develop autoimmune disease (AID), and the risk of AID increased with rising ANA titres.
Disclaimer: Information provided on this website is only for medical education purposes and not intended as medical advice. Although authors have made every effort to provide up-to-date information, the recommendations should not be considered standard of care. Responsibility for patient care resides with the doctors on the basis of their professional license, experience, and knowledge of the individual patient. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse effects, please refer to the approved product label. Neither the authors nor publisher shall be liable or responsible for any loss or adverse effects allegedly arising from any information or suggestion on this website. This website is written for use of healthcare professionals only; hence person other than healthcare workers is advised to refrain from reading the content of this website.